Selected article for: "SARS CoV spike protein and spike protein"

Author: Roman Woelfel; Victor Max Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Mueller; Daniela Niemeyer; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Bruenink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Title: Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
  • Document date: 2020_3_8
  • ID: gunn55f9_18
    Snippet: Seroconversion was detected by IgG and IgM immunofluorescence using cells expressing the spike protein of SARS-CoV-2 and a virus neutralization assay using SARS-CoV-2 ( Table 3 ). In early sera, taken between day 3 and 6, none of the patients showed detectable antibody. The patients monitored long enough to yield a serum sample after two weeks all showed neutralizing antibodies, the titer levels of which did not suggest any correlation with cli.....
    Document: Seroconversion was detected by IgG and IgM immunofluorescence using cells expressing the spike protein of SARS-CoV-2 and a virus neutralization assay using SARS-CoV-2 ( Table 3 ). In early sera, taken between day 3 and 6, none of the patients showed detectable antibody. The patients monitored long enough to yield a serum sample after two weeks all showed neutralizing antibodies, the titer levels of which did not suggest any correlation with clinical courses. Of note, case #4, with the lowest virus neutralization titer at end of week 2, seemed to shed virus from stool over prolonged time (Figure 2 D) . Results on differential recombinant immunofluorescence assay indicated no significant rise in titer against the four endemic human Coronaviruses (Table S1) .

    Search related documents:
    Co phrase search for related documents
    • clinical course and IgM immunofluorescence: 1, 2
    • clinical course and immunofluorescence assay: 1, 2, 3, 4
    • clinical course and long monitor: 1
    • clinical course and prolong time: 1
    • clinical course and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • detectable antibody and neutralize antibody: 1
    • detectable antibody and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • detectable antibody show and SARS spike protein: 1
    • differential recombinant immunofluorescence assay and immunofluorescence assay: 1
    • differential recombinant immunofluorescence assay and recombinant immunofluorescence assay: 1
    • early sera and SARS spike protein: 1, 2, 3
    • IgM immunofluorescence and immunofluorescence assay: 1, 2, 3, 4, 5
    • IgM immunofluorescence and SARS spike protein: 1
    • IgM immunofluorescence IgG detect and immunofluorescence assay: 1
    • IgM immunofluorescence IgG detect and SARS spike protein: 1
    • immunofluorescence assay and recombinant immunofluorescence assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • immunofluorescence assay and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • long monitor and SARS spike protein: 1
    • neutralize antibody and SARS spike protein: 1, 2, 3, 4